Hemab Therapeutics Holdings, Inc. (COAG)
| Market Cap | 1.94B |
| Revenue (ttm) | n/a |
| Net Income | -83.24M |
| EPS | -10.06 |
| Shares Out | 46.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 765,616 |
| Open | 40.34 |
| Previous Close | 40.42 |
| Day's Range | 39.38 - 42.85 |
| 52-Week Range | 23.00 - 55.42 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 62.67 (+51.19%) |
| Est. Earnings | Nov 13, 2026 |
About COAG
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for COAG stock is "Strong Buy." The 12-month stock price target is $62.67, which is an increase of 51.19% from the latest price.
News
Hemab Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Joyce Zhou initiated coverage of Hemab Therapeutics (COAG) with an Overweight rating and $70 price target The firm says the company has an emerging pipeline of early to…
Hemab Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $56 price target The firm cites sutacimig’s path to becoming the first approved prophylactic therapy in…
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the Board Keli Walbert brings two decades of commercial leadership and proven track record of...
Hemab Therapeutics doses first patient in HMB-003 trial
Hemab Therapeutics (COAG) announced that the first healthy volunteer has been dosed in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy menstrual b...
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care f...
Hemab Therapeutics price target raised to $64 from $55 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Hemab Therapeutics (COAG) to $64 from $55 and keeps an Outperform rating on the shares. The firm notes the company…
Hemab Therapeutics Holdings Slides: Corporate presentation
Hemab Therapeutics Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Hemab Therapeutics price target raised to $60 from $52 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Hemab Therapeutics (COAG) to $60 from $52 and keeps a Buy rating on the shares post the Q2 report. The firm says…
Hemab Therapeutics Holdings Earnings release: Q2 2026
Hemab Therapeutics Holdings released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Hemab Therapeutics Holdings Quarterly report: Q2 2026
Hemab Therapeutics Holdings has published its Q2 2026 quarterly earnings report on August 11, 2026.
Hemab Therapeutics presents sutacimig data at ISTH Congress
Hemab Therapeutics (COAG) presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Haemostasis, or ISTH, 2026 Congress in Paris, France. Th...
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026
Hemab Therapeutics price target raised to $47 from $39 at Jefferies
Jefferies raised the firm’s price target on Hemab Therapeutics (COAG) to $47 from $39 and keeps a Buy rating on the shares after competitor Incyte’s (INCY) Star unit reported additional…
Hemab Therapeutics price target raised to $55 from $42 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Hemab Therapeutics (COAG) to $55 from $42 and keeps an Outperform rating on the shares. HMB-002 showed promising clinical data…
Hemab Therapeutics price target raised to $52 from $40 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Hemab Therapeutics (COAG) to $52 from $40 and keeps a Buy rating on the shares following the updated HMB-002…
Hemab Therapeutics presents new clinical data from HMB-002 in VWD
Hemab Therapeutics (COAG) presented new clinical data from HMB-002 in Von Willebrand disease, VWD, and announced the HMB-003 program at the International Society on Thrombosis and Haemostasis, ISTH, 2...
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of pea...
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing;...
Hemab Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $40 price target Hemab is a mid-stage biotech building “first-in-class” antibody franchises with subcutaneous prop...
Hemab Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a pipeline of therapies for rare bleeding disorders, with its lead asset entering phase III and additional programs progressing in Factor VII deficiency and von Willebrand disease. Strong efficacy, regulatory alignment, and a robust financial position support global development plans.
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment o...
Hemab Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $50 price target citing the combination of significant unmet need, limited competition and multiple upcoming ...
Wedbush bullish on Hemab Therapeutics, initiates with an Outperform
As previously reported, Wedbush analyst David Nierengarten initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $42 price target The firm views Hemab Therapeutics as a high co...
Hemab Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated coverage of Hemab Therapeutics (COAG) with an Outperform rating and $42 price target
Hemab Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft initiated coverage of Hemab Therapeutics (COAG) with a Buy rating and $39 price target The company is positioned transform care in rare bleeding disorders, similar to…